Novartis AG ADR (NVS)vsQuoin Pharmaceuticals Ltd DRC (QNRX)
NVS
Novartis AG ADR
$146.57
-0.87%
HEALTHCARE · Cap: $282.11B
QNRX
Quoin Pharmaceuticals Ltd DRC
$6.21
-4.17%
HEALTHCARE · Cap: $9.83M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
QNRX
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$146.57
$36.97 premium
Intrinsic value data unavailable for QNRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : QNRX
The strongest argument for QNRX centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : QNRX
The primary concerns for QNRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while QNRX is a value play — different risk/reward profiles.
QNRX carries more volatility with a beta of 1.82 — expect wider price swings.
QNRX is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Quoin Pharmaceuticals Ltd DRC
HEALTHCARE · BIOTECHNOLOGY · USA
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology company dedicated to developing innovative therapeutics targeting rare diseases and unmet medical needs. Leveraging advanced drug delivery technologies, Quoin aims to improve the efficacy and safety of existing compounds, thereby strengthening its foothold in the specialty pharmaceuticals landscape. The company's promising pipeline features therapies addressing critical health conditions, offering potential for significant clinical advancements and commercial opportunities. Committed to delivering value for patients and investors alike, Quoin actively pursues strategic collaborations and pioneering research initiatives.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?